Precision BioSciences reports Q4 EPS $1.05, consensus (64c)

Reports Q4 revenue $34.2M, consensus $9.07M. The increase of $33.6M in revenue during the quarter ended December 31, 2025 was primarily the result of recognizing $26.2M in revenue under the Novartis agreement following conclusion of the hemoglobinopathy collaboration in October 2025 and recognition of $8M in revenue under the Imugene license agreement. “2025 was an exceptional year for Precision BioSciences (DTIL) marked by meaningful clinical and financial progress. We delivered on what we committed to achieve and more in 2025 positioning Precision BioSciences for success in 2026 and beyond,” said Michael Amoroso, Chief Executive Officer. “The evidence supporting the clinical utility of ARCUS for in vivo gene editing continues to mount in diseases with high unmet need led by advancement of PBGENE-HBV through multiple cohorts in our ELIMINATE-B study for chronic hepatitis B. At The Liver Meeting(R) 2025, we presented late-breaking clinical data showing safety and cumulative, dose-dependent antiviral activity along with paired biopsy findings that provide the first molecular evidence consistent with viral DNA gene editing in patients. In another first, our partner iECURE achieved a complete response in the first infant with neonatal onset OTC deficiency following treatment with ECUR-506 which utilizes an ARCUS nuclease developed by Precision for in vivo gene insertion.”